BMRA Nasdaq In Vitro & In Vivo Diagnostic Substances Financials FY2017βFY2026
Biomerica Inc had $4.5M of revenue in fiscal 2026, down 16.2% on the year before. Over five years, revenue changed β9.2% a year on average.
Last close Β· Oct 23, 2026
$1.68
0.0%Hi! I read Biomerica Incβs latest annual report (fiscal 2026). Here is what stands out:
Good So-so Weak
Are sales growing?
β16.2%
No. Sales fell 16.2% last year.
Does it make a profit?
β84.8%
No. It lost money last year.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
β
No P/E: it made no profit over the last four quarters.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Biomerica Inc did it, and the next one. Share prices often move a lot on those days.
Next results
January 13, 2027
Wednesday Β· in 79 days
Estimated from the same quarter last year. It will be replaced by the announced date once there is one.
See who else reports that week β| Date | Results for | Time | Source |
|---|---|---|---|
| Oct 15, 2026 | Q1 '27 | After the market closes | 10-Q β |
| Aug 31, 2026 | Q4 '26 | After the market closes | 10-K β |
| Apr 13, 2026 | Q3 '26 | After the market closes | 10-Q β |
| Jan 14, 2026 | Q2 '26 | After the market closes | 10-Q β |
| Oct 14, 2025 | Q1 '26 | After the market closes | 10-Q β |
| Aug 29, 2025 | Q4 '25 | After the market closes | 10-K β |
| Apr 14, 2025 | Q3 '25 | After the market closes | 10-Q β |
| Jan 14, 2025 | Q2 '25 | After the market closes | 10-Q β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Biomerica Inc had $4.5M of revenue in fiscal 2026, down 16.2% on the year before. Over five years, revenue changed β9.2% a year on average. Its operating margin was β119.5%, down 22.7Β pts: of every 100 in sales, about β119 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Biomerica Inc lost $3.8M in fiscal 2026.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Biomerica Inc can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash and short-term investments | $5.9M | $9.7M | $4.2M | $2.4M | $1.3M |
| Current ratio | 4.7x | 6.6x | 3.5x | 2.8x | 1.6x |
| Quick ratio | 3.5x | 5.5x | 2.4x | 1.9x | 0.9x |
| Total assets | $11.4M | $14.5M | $9.3M | $5.9M | $6.8M |
| Total liabilities | $3.0M | $2.7M | $2.7M | $1.8M | $4.1M |
| Shareholders' equity | $8.3M | $11.7M | $6.6M | $4.1M | $2.6M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· Biomerica Inc passes 2 of 8 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 1 / 8 | 1 / 8 | 3 / 8 | 2 / 8 | 4 / 8 | 2 / 8 | 4 / 8 | 2 / 8 | 2 / 8 |
| Accruals ratio | β3.7% | β5.7% | β2.8% | 14.4% | β15.1% | β34.9% | β12.9% | β5.2% | β14.9% | β5.6% |
| Altman Z'' | 2.23 | β3.07 | β7.92 | 4.52 | β4.55 | β5.59 | β3.45 | β15.08 | β29.16 | β30.60 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $5.8M | $5.6M | $5.2M | $6.7M | $7.2M | $18.9M | $5.3M | $5.4M | $5.3M | $4.5M |
| Gross profit | $2.0M | $1.8M | $1.3M | $1.7M | $0.4M | $3.0M | $0.4M | $0.6M | $0.5M | $0.4M |
| Research and development | $1.1M | $1.4M | $1.7M | $1.9M | $2.2M | $1.8M | $1.6M | $1.5M | $1.0M | $0.8M |
| Operating income | β$1.0M | β$1.5M | β$2.4M | β$2.7M | β$7.5M | β$4.5M | β$7.2M | β$6.4M | β$5.1M | β$5.3M |
| Interest expense | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | β | β | β | β | β |
| Pretax income | β$0.9M | β$1.4M | β$2.4M | β$2.7M | β$7.4M | β$4.5M | β$7.1M | β$5.9M | β$5.0M | β$3.8M |
| Income tax | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.0M |
| Net income | β$0.9M | β$1.5M | β$2.4M | β$2.7M | β$7.4M | β$4.5M | β$7.1M | β$6.0M | β$5.0M | β$3.8M |
| Diluted EPS | β$0.11 | β$0.17 | β$0.26 | β$0.26 | β$0.62 | β$0.36 | β$0.50 | β$2.84 | β$2.16 | β$1.30 |
| Diluted shares | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.01B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$0.7M | β$1.2M | β$2.2M | β$4.3M | β$5.3M | β$0.5M | β$5.5M | β$5.4M | β$3.8M | β$3.4M |
| Capital expenditure | $0.1M | $0.1M | $0.1M | $0.0M | $0.1M | $0.1M | $0.1M | $0.1M | β | β |
| Free cash flow | β$0.8M | β$1.3M | β$2.3M | β$4.3M | β$5.4M | β$0.5M | β$5.5M | β$5.4M | β | β |
| Depreciation and amortization | $0.1M | $0.1M | $0.1M | $0.1M | $0.1M | $0.3M | $0.1M | $0.1M | $0.1M | $0.1M |
| Stock-based compensation | β | $0.0M | $0.2M | β | $1.4M | $1.3M | $1.2M | $0.8M | $0.5M | $0.5M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.2M | $1.2M | $0.7M | $8.6M | $4.2M | $5.9M | $9.7M | $4.2M | $2.4M | $1.3M |
| Current assets | $4.2M | $4.5M | $4.5M | $14.8M | $9.2M | $9.4M | $12.8M | $7.7M | $4.9M | $4.0M |
| Current liabilities | $0.5M | $0.9M | $1.3M | $1.5M | $1.3M | $2.0M | $1.9M | $2.2M | $1.7M | $2.5M |
| Inventory | $1.7M | $2.2M | $2.2M | $2.9M | $3.2M | $2.4M | $2.1M | $2.4M | $1.5M | $1.7M |
| Property and equipment, net | $0.3M | $0.4M | $0.4M | $0.3M | $0.3M | $0.2M | $0.2M | $0.2M | $0.1M | $0.1M |
| Intangible assets | $0.2M | $0.1M | $0.1M | $0.2M | $0.3M | $0.2M | $0.2M | $0.2M | $0.2M | $0.2M |
| Total assets | $5.0M | $5.2M | $5.2M | $17.3M | $11.8M | $11.4M | $14.5M | $9.3M | $5.9M | $6.8M |
| Total liabilities | $0.5M | $0.9M | $1.3M | $3.0M | $2.6M | $3.0M | $2.7M | $2.7M | $1.8M | $4.1M |
| Preferred stock | β | β | β | $0.0M | β | β | β | β | β | β |
| Shareholders' equity | $4.5M | $4.3M | $4.0M | $14.2M | $9.2M | $8.3M | $11.7M | $6.6M | $4.1M | $2.6M |
| Margins | ||||||||||
| Gross margin | 34.9% | 31.5% | 24.8% | 26.0% | 5.1% | 15.8% | 8.4% | 11.3% | 9.4% | 8.1% |
| Operating margin | β16.5% | β26.6% | β46.4% | β41.0% | β104.2% | β24.0% | β135.3% | β117.6% | β96.7% | β119.5% |
| EBITDA margin | β14.0% | β24.6% | β44.4% | β39.4% | β102.7% | β22.2% | β133.7% | β116.1% | β95.1% | β117.7% |
| Net margin | β15.7% | β26.3% | β46.0% | β40.0% | β103.4% | β24.0% | β133.7% | β110.4% | β93.6% | β84.8% |
| FCF margin | β14.1% | β23.4% | β45.1% | β64.7% | β74.8% | β2.8% | β103.7% | β99.9% | β | β |
| Returns | ||||||||||
| Return on capital employed | β21.3% | β34.3% | β60.6% | β17.4% | β71.3% | β48.4% | β57.7% | β90.3% | β122.2% | β124.4% |
| Return on equity | β20.2% | β33.3% | β57.6% | β29.4% | β63.5% | β51.6% | β71.2% | β65.3% | β93.0% | β112.1% |
| Return on assets | β18.1% | β28.6% | β45.7% | β23.8% | β51.2% | β39.1% | β55.3% | β50.4% | β65.4% | β59.4% |
| Return on tangible equity | β21.1% | β34.7% | β61.8% | β19.1% | β83.4% | β55.6% | β61.8% | β93.7% | β128.3% | β155.9% |
| Growth | ||||||||||
| Revenue growth | β | β3.9% | β6.5% | 28.7% | 7.6% | 162.1% | β71.7% | 1.4% | β1.9% | β16.2% |
| Share count change | β | 2.9% | 7.5% | 10.4% | 17.3% | 6.2% | 11.7% | β85.1% | 9.2% | 26.9% |
| Financial health | ||||||||||
| Interest coverage | β3,182.0x | β | β | β | β18,749.3x | β | β | β | β | β |
| Current ratio | 8.0x | 5.0x | 3.6x | 10.0x | 7.1x | 4.7x | 6.6x | 3.5x | 2.8x | 1.6x |
| Quick ratio | 4.7x | 2.6x | 1.9x | 8.1x | 4.6x | 3.5x | 5.5x | 2.4x | 1.9x | 0.9x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.7% | 2.3% | 1.9% | 0.5% | 1.9% | 0.3% | 1.2% | 0.9% | β | β |
| Stock comp / revenue | β | 0.3% | 2.9% | β | 18.8% | 6.7% | 22.2% | 15.5% | 8.7% | 10.7% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 1.0 | 1.0 | 3.0 | 2.0 | 4.0 | 2.0 | 4.0 | 2.0 | 2.0 |
| Altman Z'' | 2.2 | β3.1 | β7.9 | 4.5 | β4.5 | β5.6 | β3.4 | β15.1 | β29.2 | β30.6 |
| Accruals ratio | β3.7% | β5.7% | β2.8% | 14.4% | β15.1% | β34.9% | β12.9% | β5.2% | β14.9% | β5.6% |
Source: SEC EDGAR XBRL filings (CIK 0000073290). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
